GLPG3667
TYK2
Small molecule
DMSLE
Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of potential best-in-class therapies.
In October 2025, the Galapagos Board of Directors decided to pursue an intention to wind down the Company’s cell therapy activities. Following completion of consultations with works councils in Belgium and the Netherlands, implementation of the wind-down was initiated in January 2026. Exiting the cell therapy business reflects Galapagos’ commitment to defining a clear and sustainable path forward and focusing its efforts where it can create the greatest patient and shareholder value.
DMSLE
SLE: Systemic lupus erythematosus; DM: Dermatomyositis
At Lakefront Biotherapeutics, we organize clinical trials in various therapeutic areas, conducting research that paves the way for innovative medicines.